chemoradiotherapy

15 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

news

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY|Jul 20, 2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc

news

chemoradiotherapy

Latest news

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma

Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

Optimizing Twice-Daily Thoracic Radiotherapy Dosage in Limited-Stage Small-Cell Lung Cancer: Impact on Survival and Toxicity

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial

Sequential Chemoradiotherapy vs Induction Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety Insights from a Phase 3 Randomized Trial

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial